I don't think anyone should look into the scheduled CC as positive or negative. All it says to me is that they want to discuss the FDA results whether it's approved or not. If it's approved, they talk about possible partnerships and/or the next steps. If it's not, they talk about Menadione and how there are still other products in the pipeline that could make TLON successful. The worst they could do is not say anything, so either way they will be prepared to make statements to the shareholders. After all, the CEO said he has the shareholders best interests in mind.
Market Data 
Markets 
AI
